Mirae Asset Global Investments Co., Ltd. Avidity Biosciences, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,976 shares of RNA stock, worth $119,439. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,976

Previous 4,236 6.14%

Holding current value

$119,439

Previous $194,000 40.72%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$29.08 - $52.5 $7,560 - $13,650	-260 Reduced 6.14%	3,976 $115,000
Q3 2024 Oct 23, 2024	BUY	$37.21 - $48.14 $51,387 - $66,481	1,381 Added 48.37%	4,236 $194,000
Q2 2024 Jul 30, 2024	SELL	$22.73 - $40.85 $786,617 - $1.41 Million	-34,607 Reduced 92.38%	2,855 $116,000
Q1 2024 May 01, 2024	SELL	$9.16 - $25.52 $1.18 Million - $3.28 Million	-128,557 Reduced 77.44%	37,462 $956,000
Q4 2023 Jan 24, 2024	BUY	$4.87 - $9.37 $606,962 - $1.17 Million	124,633 Added 301.15%	166,019 $1.5 Million
Q3 2023 Oct 26, 2023	SELL	$6.3 - $11.35 $50,280 - $90,584	-7,981 Reduced 16.17%	41,386 $264,000
Q2 2023 Aug 10, 2023	BUY	$10.62 - $17.34 $73,320 - $119,715	6,904 Added 16.26%	49,367 $547,000
Q1 2023 May 04, 2023	BUY	$15.35 - $25.65 $264,649 - $442,231	17,241 Added 68.36%	42,463 $651,000
Q4 2022 Feb 09, 2023	BUY	$10.06 - $22.66 $34,274 - $77,202	3,407 Added 15.62%	25,222 $559,000
Q3 2022 Nov 10, 2022	BUY	$15.46 - $23.43 $150,410 - $227,950	9,729 Added 80.5%	21,815 $356,000
Q2 2022 Jul 26, 2022	BUY	$11.18 - $20.5 $135,121 - $247,763	12,086 New	12,086 $175,000

Others Institutions Holding RNA

# of Institutions

258

Shares Held

108M

Call Options Held

517K

Put Options Held

717K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.57B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Avidity Biosciences, Inc. Transaction History